From Later Lines to Front Lines, New ADCs Bring Survival Benefits to More Patients with HER2 Overexpression and HER2 Ultra-Low Expression

From Later Lines to Front Lines, New ADCs Bring Survival Benefits to More Patients with HER2 Overexpression and HER2 Ultra-Low Expression

The mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) was held from June 28-30, 2024, in Shanghai, where young elites from across the country gathered to discuss academic progress. Recent updates and announcements from various DESTINY-Breast (DB) series studies have brought more benefits to patients with HER2-positive, HER2-low, and HER2 ultra-low expression. Oncology Frontier invited Professor Rui Ge from Fudan University Shanghai East Hospital to share the latest findings from the DB series and to discuss the future treatment landscape for HER2-positive breast cancer.
Professor Simon J. Crabb: Evaluating Self-Help CBT for Hot Flushes and Night Sweats in Prostate Cancer Patients on ADT in the MANCAN2 Study

Professor Simon J. Crabb: Evaluating Self-Help CBT for Hot Flushes and Night Sweats in Prostate Cancer Patients on ADT in the MANCAN2 Study

ASCO International Perspective | experience hot flushes and night sweats (HFNS), which not only decrease their quality of life but may also affect compliance with ADT. Current relief methods are limited. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Simon J. Crabb from the University Hospital Southampton presented the results of the MANCAN2 study. "Oncology Frontier" invited Professor Simon J. Crabb to share his thoughts on managing prostate cancer.
BOC/BOA 2024 | Professor Tian Yang: Annual Advances in Chinese Clinical Oncology 2023 (Hepatobiliary and Pancreatic Tumors)

BOC/BOA 2024 | Professor Tian Yang: Annual Advances in Chinese Clinical Oncology 2023 (Hepatobiliary and Pancreatic Tumors)

Since 2015, the Chinese Society of Clinical Oncology (CSCO) has adhered to the philosophy of "International Standards, Chinese Characteristics, Learning and Absorbing, Innovating and Improving," launching the "Annual Research Advances in Chinese Clinical Oncology" for nine consecutive years. At the recently held "2024 Annual Progress Seminar on Chinese Clinical Oncology (BOC) and Best of ASCO 2024 China," the "Annual Research Advances in Chinese Clinical Oncology 2023" was officially released. Professor Tian Yang from The Third Affiliated Hospital of Naval Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital) reported on the "Annual Research Advances in Chinese Clinical Oncology 2023 (Hepatobiliary and Pancreatic Tumors)." The report is summarized below.
Professor Qing Xie: Contributions and Challenges of Long-Acting Interferon in the Clinical Cure of Chronic Hepatitis B

Professor Qing Xie: Contributions and Challenges of Long-Acting Interferon in the Clinical Cure of Chronic Hepatitis B

Antiviral treatment can maximize the long-term suppression of hepatitis B virus (HBV) DNA replication, reducing liver necrosis, fibrosis, cirrhosis, liver cancer, and other complications, thereby improving the quality of life and extending the survival time of hepatitis B patients. Currently, long-acting interferon is recommended as a first-line treatment option by guidelines in Europe, the United States, the Asia-Pacific region, and China. Long-acting interferon treatment for chronic hepatitis B (CHB) offers a greater probability of achieving clinical cure and is also the most effective means of reducing the risk of liver cancer. Recently, at the 17th National Conference on Clinical Liver Diseases in 2024, Professor Qing Xie from Ruijin Hospital presented a report titled "Contributions and Challenges of Long-Acting Interferon in the Clinical Cure of Chronic Hepatitis B." This article from Hepatology Digest summarizes the report for our readers.
APACC2024 | Dr. Chunyan Li: Service Provision and Adherence Support for HIV Pre-Exposure Prophylaxis (PrEP)

APACC2024 | Dr. Chunyan Li: Service Provision and Adherence Support for HIV Pre-Exposure Prophylaxis (PrEP)

Numerous studies have explored the use of long-acting antiretroviral therapy (Long-acting ART) for HIV pre-exposure prophylaxis (PrEP), achieving positive preventive outcomes. However, the promotion of long-acting PrEP still faces many challenges. Additionally, how can adherence to existing oral PrEP regimens be further improved? At the recently held 9th Asia Pacific AIDS & Co-infections Conference (APACC 2024), Dr. Chunyan Li from the The University of Tokyo Institutes for Advanced Study participated in several panel discussions and shared her team's research findings, offering more insights and reflections on these issues.
Exempting RNI in Post-BCS pN1 Breast Cancer Patients Who Have Undergone Taxane-Based Chemotherapy

Exempting RNI in Post-BCS pN1 Breast Cancer Patients Who Have Undergone Taxane-Based Chemotherapy

For most patients, postoperative radiotherapy plays a crucial role. Some early-stage breast cancer patients require prophylactic regional lymph node irradiation (RNI) in addition to whole-breast irradiation (WBI). However, the survival benefit of RNI for patients with 1-3 positive axillary lymph nodes (pN1) remains uncertain. Therefore, it's necessary to evaluate the impact of RNI on the prognosis of pN1 breast cancer patients receiving systemic therapy. At the 2024 ASCO Conference, Korean researchers initiated the KROG 1701 study (Abstract 577) to explore this issue. "Oncology Frontier" invited Professor Yanxia Zhao from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, to interpret and comment on this study.
Standardized Diagnosis and Treatment with Innovative Breakthroughs, Ushering in a Golden Era for China’s Hematologic Oncology Field

Standardized Diagnosis and Treatment with Innovative Breakthroughs, Ushering in a Golden Era for China’s Hematologic Oncology Field

From July 5 to 7, 2024, the highly anticipated 2024 Annual Progress Seminar on Chinese Clinical Oncology (BOC) and Best of ASCO 2024 China was grandly held in Guangzhou. The conference focused on the "Annual Research Advances in Chinese Clinical Oncology 2023," selected by the Chinese Society of Clinical Oncology (CSCO), aiming to delve into the latest research achievements in China's oncology field. Given the actual situation of cancer incidence in China, the conference specially invited authoritative experts in the field of oncology to comprehensively and deeply interpret outstanding papers from the 2024 ASCO meeting across various oncology disciplines. During the conference, Oncology Frontier - Hematology Frontier invited Professor Jun Zhu from Peking University Cancer Hospital for an exclusive interview to share his profound insights and unique academic perspectives on the conference.
ASCO International Perspective | Professor Samuel R. Denmeade: Biomarkers for Bipolar Androgen Therapy in mCRPC

ASCO International Perspective | Professor Samuel R. Denmeade: Biomarkers for Bipolar Androgen Therapy in mCRPC

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. In a recent late-breaking abstract (LBA) report, Professor Samuel R. Denmeade from Johns Hopkins University School of Medicine shared the specific results of the TRANSFORMER trial. This randomized trial targeted abiraterone-pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, aiming to identify blood biomarkers. "Oncology Frontier" had the opportunity to interview Professor Samuel R. Denmeade to highlight the potential benefits and future directions of bipolar androgen therapy (BAT), a new treatment approach.
Breaking Through – Promising Results from Phase I Study of KSD-101 Dendritic Cell Vaccine in Treating EBV-Positive Hematologic Malignancies

Breaking Through – Promising Results from Phase I Study of KSD-101 Dendritic Cell Vaccine in Treating EBV-Positive Hematologic Malignancies

Epstein-Barr virus (EBV) infection is widespread among adults, yet there is no standard treatment for EBV-positive hematologic malignancies, leading to poor patient outcomes. At the 29th Annual Meeting of the European Hematology Association (EHA), Professor Chunrui Li from Tongji Hospital of Huazhong University of Science and Technology presented the results of her team’s Phase I exploratory trial of the KSD-101 dendritic cell vaccine in treating EBV-related hematologic malignancies. This study brings new hope for treating these diseases. Oncology Frontier-Hematology Frontier interviewed Professor Li to delve into this innovative research and discuss the potential impact of KSD-101 on the future of hematologic malignancy treatment.
EHA 5-Minute Interview | Professor Minghui Duan: Latest Advances in Myelofibrosis Treatment

EHA 5-Minute Interview | Professor Minghui Duan: Latest Advances in Myelofibrosis Treatment

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). At the 29th European Hematology Association (EHA) Annual Meeting held in Madrid, Spain, from June 13 to 16, 2024, notable advancements were made in MPN research. Oncology Frontier-Hematology Frontier invited Professor Minghui Duan from the Department of Hematology, Peking Union Medical College Hospital, to introduce and provide an in-depth review of two significant studies on myelofibrosis treatment. We hope Professor Duan's insights will help us understand the research progress in this field and provide important references for future research and treatment.